Eli Lilly Patent Cliff — Generic Weight-Loss Drugs Gain Ground in India
10 Apr, 20:13 IST · Plays out over months · 1 source
Key facts
What the reporting establishes, before any reading of it.
- Eli Lilly market share stumbling as generic weight-loss drugs gain ground in India
- Patent cliff enabling Indian generic manufacturers to enter massive obesity/diabetes drug market
- GLP-1 drug market valued at $50B+ globally — Indian generics capturing domestic share
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- Eli Lilly loses India market share to generic GLP-1 manufacturers
Who may gain
- Indian generic pharma companies with GLP-1 manufacturing capability — Natco, Zydus, Lupin, Glenmark
Along the supply chain
Downstream
Indian hospitals and pharmacies benefit from higher generic availability
Upstream
API manufacturers for GLP-1 active ingredients see demand surge
Where demand moves
Business
Patient demand shifts from branded to affordable Indian generics — volumes surge for domestic players
Capital
Pharma sector rotation from overvalued names to generics players with GLP-1 exposure
How it spreads across sectors
CDMO
Contract manufacturers may receive orders from global generic players
Healthcare
Structural positive for Indian generics sector
When it plays out
Immediate
Pharma stocks with GLP-1 exposure see buying
Medium term
Indian generic penetration in obesity drugs creates multi-year revenue stream
Short term
Watch for ANDA filings and regulatory approvals